JOURNAL CONTENT
CONTACT

Submission of the manuscript is online via e-mail
ecgarticle@gmail.com or
cholerez@mail.ru

Tel: +7 903 250 5288

Editorial Correspondence e-mail
gastrossr@gmail.com


Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail
journal@cniig.ru

Tel: +7 917 561 9505

THE RULES OF SUBMITTING AN ARTICLE

READ

Scimago Journal & Country Rank

SCImago Journal & Country Rank

CLINICAL GASTROENTEROLOGY

    1. Saratov State Medical University n. a. V. I. Razumovsky (Saratov, Russian Federation)

    Keywords:comorbid diseases,postgastrectomy disturbances,periodontal disease

    Abstract:Purpose. Definition of features of a periodontal tissues at patients with postgastrectomy disturbances and predictors of progression periodontal diseases Material and methods. The examination of 42 patients with a disease of the operated stomach and chronic generalized periodontitis at the age of 29-58 years is conducted. Endoscopic, radiological, morphological examination is conducted. Material processed statistically. Results. Clinical features of a periodontal disease against the background of the postgastrectomy disturbances are the expressed inflammatory reaction in periodontal tissues, deep periodontal pockets, suppuration from them, appreciable mobility of teeth, plentiful tooth deposits, erosions of an enamel. Predictors of emergence and advance of a periodontal disease after a resection of a stomach are disturbance of evacuation from a stomach stump, the expression of an enterogastro-ezofageal reflux, general dystrophic changes in an organism caused by malabsorption. Conclusion. Achievement of permanent remission in treatment of patients with comorbid pathology requires joint approach of gastroenterologists and stomatologists.

      1. Ивашкин В. Т., Комаров Ф. И., Раппопорт С. И. Краткое руководство по гастроэнтерологии. М.: Медицинское информационное агентство. 2001: 457.
      2. Самсонов М. А., Лоранская Т. И., Нестерова А. П. Постгастрорезекционные синдромы. М.: Медицина. 1984: 192.
      3. Осадчук М. А., Островская Л. Ю., Исламова Е. А. Особенности лечения пациентов с язвенной болезнью желудка и двенадцатиперстной кишки, сочетанной с воспалительными заболеваниями пародонта. Вестник Волгоградского государственного медицинского университета 2009; 1: 76-80.
      4. Горбачева И. А., Орехова Л. Ю., Сычева Ю. А. и соавт. Воспалительные заболевания пародонта в полиморбидном континууме, интегративный подход к лечению. СПб.: ООО «АСпринт». 2012: 140.
      5. Калинина А. В., Логинова А. Ф., Хазанова А. И. Гастроэнтерология и гепатология: диагностика и лечение: руководство для врачей. М.: МЕДпресс-информ. 2013: 848.
      6. Маев И. В. Внепищеводные проявления гастроэзофагеальной рефлюксной болезни. Рос. журн. гастроэнтерол., гепатол., колопрок-тол. 2005; 5: 56-67.
      7. Горбачева И. А., Орехова Л. Ю., Сычева Ю. А. Пути преодоления полипрагмазии при лечении современных полиморбидных больных с воспалительными заболеваниями пародонта. Пародонтология 2015; 2(75): 15-18.
      8. Булкина Н. В., Ведяева А. П., Савина Е. А. Коморбидность заболеваний пародонта и соматической патологии. Медицинский вестник Северного Кавказа 2012; 3: 110-115.
      9. Цепов Л. М. Заболевания пародонта: взгляд на проблему. М.: МЕДпресс-информ. 2006: 192.
     


    Full text is published :
    Ostrovskaya L.U., Bulkina N.V. CONDITION OF PERIODONTAL TISSUES AT PATIENTS WITH POSTGASTRECTOMY SYNDROM. Experimental and Clinical Gastroenterology Journal. 2017;144(08):12-16
    Read & Download full text

    1. Medical Academy named after S. I. Georgievsky, Crimean Federal University named after V. I. Vernadsky (Simferopol, Russian Federation)

    Abstract:Objective: individualization of therapy in patients with pulmonary tuberculosis and in HIV-coinfected patients who are undergoing antituberculosis and antiretroviral therapy, by studying the risk factors of drug-induced liver disease (polymorphism of NAT2 and cytochrome P450 2E 1). Materials and methods. 200 patients were examined during the study. 120 patients with newly diagnosed pulmonary tuberculosis (TB) who were undergoing anti-tuberculosis therapy according to I or III regimens have been identified among them. Patients with or without drug-induced liver disease on the background of anti-tuberculosis chemotherapy were studied by genotyping of cytochrome P450 2E 1 and NAT2 enzymes by «real time» polymerase chain reaction (PCR) and 13C-metacetin breath test. Results. In the 2 nd group and in the 4 th group (in groups of patients with drug-induced liver disease on the background of antituberculous therapy), slow acetylators and genotype of cytochrome P450 2E 1 c1 / c1 prevailed. Conclusions. It is advisable to recommend patients in the high-risk group for the development of drug-induced liver disease to determine the activity of cytochrome P450 2E 1 and NAT2 enzymes by genotyping and phenotyping in order to select the optimal scheme of anti-tuberculosis therapy, which will lead to increased adherence of patients to therapy and improvement of patients’ quality of life.

      1. Plan to Stop TB in 18 High-priority Countries in the WHO European Region, 2007-2015. World Health Organization.
      2. Global tuberculosis report 2013. Geneva, Switzerland: WHO; 2013. World Health Organization. WHO/HTM/TB/2013.11.http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf. Accessed September 2014.
      3. «Государственная программа Российской федерации: развитие здравоохранения». Распоряжение правительства Российской Федерации от 24 декабря 2012 г. № 2511- р.
      4. Уточненный отчет о ходе реализации и оценке эффективности государственной программы Российской Федерации «Развитие здравоохранения» за 2014 год. https://www.rosminzdrav.ru/ministry/programms/health/info
      5. Государственная программа Российской Федерации «Развитие здравоохранения» Постановление правительства Российской Федерации. От 15 апреля 2014 года N 294
      6. Перельман М. И. Фтизиатрия. Национальное руководство. - 2011 год
      7. Баласанянц Г. С. Гепатотоксические реакции и гепатопротективная терапия во фтизиатрии. «Туберкулез и болезни легких», 2015, № 8, с. 48-52. ФГБУ «СПбНИИФ» М3 РФ, г. Санкт-Петербург
      8. GUIDELINE Consensus statement: Management of drug-induced liver injury in HIV-positive patients treated for TB Southern African Journal of HIV Medicine, Vol. 14, No 3 (2013)
      9. Иванов А. К., Шевырева Е. В., Сакра А. и др. Гепатопротективная терапия больных туберкулезом в сочетании с вирусными гепатитами и ВИЧ-инфекцией // Ж. инфектологии, прилож. - 2014. - Т. 6, № 2. - С. 43.
      10. Иванова Д. А. Нежелательные побочные реакции при лечении больных туберкулезом // Туберкулез и болезни легких 2011. № 6. 60-9.
      11. Wang J.Y., Liu C. H., Hu F. C. Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. J Infect. 2011;62:448-455. [PubMed]
      12. Ungo J.R., Jones D., Ashkin D. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998;157:1871-1876. [PubMed]
      13. Dworkin M. S., Adams M. R., Cohn D. L. Factors that complicate the treatment of tuberculosis in HIV-infected patients. J Acquir Immune Defic Syndr. 2005;39:464-470. [PubMed]
      14. Klyarytskaya, I.L., Stilidi, E.I., Maksymova, E. V. Comparison Of Different Treatment Regimens In Patients With Nonalcoholic Fatty Liver Disease // Experimental & clinical gastroenterology. - 2015. - № 17. - P. 12-17
      15. Singla R., Sharma S. K., Mohan A. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res. 2010;132:81-86. [PubMed]
      16. White M. C., Tulsky J. P., Lee J. R. Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence. J Correct Health Care. 2012;18:131-142. [PubMed]
      17. Bose P. D., Sarma M. P., Medhi S. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E 1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterol Hepatol. 2011;26:312-318. [PubMed]
      18. Wang P. Y., Xie S. Y., Hao Q. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis. 2012;16:589-595. [PubMed]
      19. Singla N, Gupta D, Birbian N, Singh J. Association of NAT2, GST and CYP2E 1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity. Tuberculosis 2014, 94: 293-298. doi: 10.1016/j.tube.2014.02.003. pmid:24637014
      20. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, et al. Cytochrome P450 2E 1 Genotype and the Susceptibility to Antituberculosis Drug - Induced Hepatitis. Hepatology 2003, 37: 924-930. pmid:12668988
      21. Мамотенко Л. Д., главный внештатный фтизиатр Министерства здравоохранения Республики Крым, 2016. http://crimea.ria.ru/society/20160321/1103890624.html
      22. Mitchell J. R., Zimmerman H. J., Ishak K. G. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med. 1976;84:181-192. [PubMed]
      23. Jussi J. Saukkonen, David L. Cohn, Robert M. Jasmer et all. An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. Am J Respir Crit Care Med Vol. 174. pp 935-952, 2006
      24. Getnet Yimer, Marcus Gry. Evaluation of Patterns of Liver Toxicity in Patients on Antiretroviral and Anti-Tuberculosis Drugs: A Prospective Four Arm Observational Study in Ethiopian Patients.Published: April 8, 2014. http://dx.doi.org/10.1371/journal.pone.0094271
      25. Кляритская И. Л., Максимова Е. В., Шелихова Е. О., Григоренко Е. И. Диагностика и тактика ведения пациентов с лекарственными поражениями печени: клинические рекомендации Американского колледжа гастроэнтерологов // Крымский терапевтический журнал. -2016. - № 1. - С. 5-11
      26. Lock, J. F. et al. Initial liver graft function is a reliable predictor of tacrolimus trough levels during the first post-transplant week. Clin Transplant 25, 436-443 (2011).
      27. Stockmann, M. et al. How to define initial poor graft function after liver transplantation? - a new functional definition by the LiMAx test. Transpl. Int. 23, 1023-1032 (2010)
      28. Максимова Е. В., Шелихова Е. О., Стилиди Е. И., Кляритская И. Л. Место 13С-метацетинового дыхательного теста в диагностике лекарственных поражений печени // Научный руководитель 2016. - № 5. - С. 58-64
      29. Кляритская И. Л., Максимова Е. В., Шелихова Е.О, Стилиди Е. И. 13С-метацетиновый дыхательный тест в гастроэнтерологической практике // Врач. - 2016. - № 7. - C.77-78
      30. Dr. A. Toure, M. Cabral, A. Niang et all. Prevention of isoniazid toxicity by NAT2 genotyping in Senegalese tuberculosis patients. Toxicology Reports 3 (2016) 826-831
      31. Vidyasagar Ramappa and Guruprasad P. Aithal. Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. J Clin Exp Hepatol. 2013 Mar; 3(1): 37-49.
      32. Huang Y. S., Chern H. D., Su W. J. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology. 2002; 35: 883-889. [PubMed]
     


    Full text is published :
    Kliaritskaia I.L., Shelikhova E.O., Maksimova E.V., Stilidi E.I. DAMAGE WHEN TAKING INFECTIONS - HUMAN IMMUNODEFI CIENCY VIRUS AND TUBERCULOSIS. Experimental and Clinical Gastroenterology Journal. 2017;144(08):17-22
    Read & Download full text